AR049487A1 - Compuestos de imidazol sustituidos - Google Patents
Compuestos de imidazol sustituidosInfo
- Publication number
- AR049487A1 AR049487A1 ARP050101299A ARP050101299A AR049487A1 AR 049487 A1 AR049487 A1 AR 049487A1 AR P050101299 A ARP050101299 A AR P050101299A AR P050101299 A ARP050101299 A AR P050101299A AR 049487 A1 AR049487 A1 AR 049487A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- alkyl
- groups
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Compuestos de imidazol sustituidos y procesos para preparar ese tipo de compuestos, su utilizacion en el tratamiento de la obesidad, trastornos psiquiátricos y neurologicos, a métodos para su utilizacion terapéutica y a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de formula (1) y sus sales aceptables para uso farmacéutico, en la cual R1 representa a) un grupo alcoxi C1-10 opcionalmente sustituido con uno o más F; b) un grupo de formula fenil(CH2)pO- en la cual p es 1, 2 o 3 y el anillo de fenilo está opcionalmente sustituido con 1, 2 o 3 grupos representados por Z; c) un grupo R5S(O)2O o R5S(O)2NH donde R5 representa un grupo alquilo C1-10 opcionalmente sustituido con uno o más F, o R5 representa fenilo o un grupo heteroarilo cada uno de los cuales está opcionalmente sustituido con 1, 2 o 3 grupos representados por Z o d) un grupo de la formula (R6)3Si en la cual R6 representa un grupo alquilo C1-6 el cual puede ser igual o diferente; Ra representa halo, un grupo alquilo C1-3 o un grupo alcoxi C1-3; m es 0, 1, 2 o 3; R2 representa un grupo alquilo C1-3, un grupo alcoxi C1-3, hidroxi, nitro, ciano o halo; n es 0, 1, 2 o 3; R3 representa a) un grupo X-Y-NR7R8, en la cual X es CO o SO2, Y está ausente o representa NH opcionalmente sustituido con un grupo alquilo C1-3; y R7 y R8 representan independientemente: un grupo alquilo C1-6 opcionalmente sustituido con 1, 2 o 3 grupos representados por W; un grupo cicloalquilo C3-15 opcionalmente sustituido con 1, 2 o 3 grupos representados por W; un grupo (cicloalquil C3-15)alquileno C1-3 opcionalmente sustituido con 1, 2 o 3 grupos representados por W; un grupo -(CH2)r(fenilo)s en el cual r es 0, 1, 2, 3 o 4, s es 1 cuando r es 0 de otro modo s es 1 o 2 y los grupos fenilo están sustituidos opcionalmente en forma independiente con uno, dos o tres grupos representados por Z; un grupo heterocíclico de 5 a 8 miembros saturado que contiene un N y opcionalmente uno de los siguientes: O, S o un N adicional donde el grupo heterocíclico está opcionalmente sustituido con uno o más grupos alquilo C1-3, hidroxi o bencilo; un grupo -(CH2)tHet en el cual t es 0, 1, 2, 3 o 4, y la cadena alquileno está opcionalmente sustituida con uno o más grupos alquilo C1-3 y Het representa un grupo heteroarilo opcionalmente sustituido con 1, 2 o 3 grupos seleccionados de un grupo alquilo C1-5, un grupo alcoxi C1-5 o halo donde el grupo alquilo y alcoxi están opcionalmente sustituidos en forma independiente con 1 o más F; o R7 representa H y R8 es segun lo definido anteriormente; o R7 y R8 junto con el átomo de N al cual están unidos representan un grupo heterocíclico de 5 a 8 miembros saturado o parcialmente insaturado que contiene un N y opcionalmente uno de los siguientes: O, S o un N adicional, donde el grupo heterocíclico está opcionalmente sustituido con uno o más grupos alquilo C1-3, hidroxi, F o bencilo; o b) oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, pirrolilo, pirazolilo, imidazolilo, triazolilo, tetrazolilo, tienilo, furilo u oxazolinilo, cada uno opcionalmente sustituido con 1, 2 o 3 grupos Z; R4 representa H, un grupo alquilo C1-6, un grupo alcoxi C1- 6 o un grupo alcoxi C1-6-alquileno C1-6 el cual contiene un máximo de 6 átomos de C, cada uno de estos grupos está opcionalmente sustituido con uno o más F o ciano; Z representa un grupo alquilo C1-3, un grupo alcoxi C1-3, hidroxi, halo, trifluormetilo, trifluormetiltio, difluormetoxi, trifluormetilsulfonilo, nitro, amino, mono o dialquilamino C1-3, alquilsulfonilo C1-3, alcoxicarbonilo C1-3, carboxi, ciano, carbamoílo, mono o dialquilcarbamoílo C1-3 y acetilo y W representa hidroxi, F, un grupo alquilo C1-3, un grupo alcoxi C1-3, amino, mono o dialquilamino C1-3 o una amina heterocíclica seleccionada entre morfolinilo, pirrolidinilo, piperidinilo o piperazinilo donde la amina heterocíclica está opcionalmente sustituida con un grupo alquilo C1-3 o hidroxilo; con la condicion de que cuando n es 1 entonces R2 no es metoxi en la posicion 2 o la posicion 4 del anillo de fenilo y con la condicion adicional de que R1 no es metilsulfonilamino, metoxi o CF3O-.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0407671A GB0407671D0 (en) | 2004-04-03 | 2004-04-03 | Therapeutic agents |
GB0420781A GB0420781D0 (en) | 2004-09-18 | 2004-09-18 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049487A1 true AR049487A1 (es) | 2006-08-09 |
Family
ID=34963354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101299A AR049487A1 (es) | 2004-04-03 | 2005-04-01 | Compuestos de imidazol sustituidos |
Country Status (14)
Country | Link |
---|---|
US (1) | US7799804B2 (es) |
EP (1) | EP1735287A1 (es) |
JP (1) | JP4177435B2 (es) |
KR (1) | KR20060133084A (es) |
AR (1) | AR049487A1 (es) |
AU (1) | AU2005229459B9 (es) |
BR (1) | BRPI0509515A (es) |
CA (1) | CA2560417C (es) |
IL (1) | IL178427A0 (es) |
NO (1) | NO20064974L (es) |
RU (1) | RU2377238C2 (es) |
TW (1) | TW200539872A (es) |
UY (1) | UY28839A1 (es) |
WO (1) | WO2005095354A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6526575B1 (en) | 1997-01-07 | 2003-02-25 | United Video Properties, Inc. | System and method for distributing and broadcasting multimedia |
JP2008525401A (ja) * | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | 治療薬 |
GB0518817D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
GB0518819D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
BRPI0709972A2 (pt) | 2006-04-14 | 2011-08-02 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
JP2009533445A (ja) | 2006-04-14 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | コレシストキニン−1受容体モジュレータとしての置換イミダゾール4−カルボキサミド |
WO2007120718A2 (en) | 2006-04-14 | 2007-10-25 | Merck & Co., Inc. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
US20100113492A1 (en) | 2007-01-26 | 2010-05-06 | Merck & Co., Inc. | Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
ES2586433T3 (es) | 2007-04-11 | 2016-10-14 | Omeros Corporation | Composiciones y métodos para la profilaxis y el tratamiento de adicciones |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
WO2014199164A1 (en) * | 2013-06-12 | 2014-12-18 | Ampla Pharmaceuticals, Inc. | Diaryl substituted heteroaromatic compounds |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE140966C (es) | ||||
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
CN1205188C (zh) * | 2000-03-23 | 2005-06-08 | 索尔瓦药物有限公司 | 具有cb1-拮抗活性的4,5-二氢-1h-吡唑衍生物 |
AU2002319627A1 (en) * | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
AR036608A1 (es) | 2001-09-24 | 2004-09-22 | Bayer Corp | Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad |
WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
ES2373875T3 (es) | 2002-03-05 | 2012-02-09 | Transtech Pharma, Inc. | Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage. |
WO2003075660A1 (en) | 2002-03-06 | 2003-09-18 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
US6799511B2 (en) * | 2002-12-03 | 2004-10-05 | Day International, Inc. | Gapless compressible cylinder assembly |
WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
PL378206A1 (pl) | 2003-01-02 | 2006-03-20 | F. Hoffmann-La Roche Ag | Nowi odwrotni agoniści receptora CB1 |
MXPA05011855A (es) | 2003-05-08 | 2006-02-17 | Astellas Pharma Inc | 1,2-diarilimidazoles utiles como inhibidores de ciclooxigenasa. |
-
2005
- 2005-03-30 BR BRPI0509515-8A patent/BRPI0509515A/pt not_active IP Right Cessation
- 2005-03-30 JP JP2007505623A patent/JP4177435B2/ja not_active Expired - Fee Related
- 2005-03-30 KR KR1020067023116A patent/KR20060133084A/ko not_active Application Discontinuation
- 2005-03-30 WO PCT/GB2005/001153 patent/WO2005095354A1/en active Application Filing
- 2005-03-30 EP EP05729088A patent/EP1735287A1/en not_active Withdrawn
- 2005-03-30 RU RU2006135482/04A patent/RU2377238C2/ru not_active IP Right Cessation
- 2005-03-30 US US11/547,048 patent/US7799804B2/en not_active Expired - Fee Related
- 2005-03-30 CA CA2560417A patent/CA2560417C/en not_active Expired - Fee Related
- 2005-03-30 AU AU2005229459A patent/AU2005229459B9/en not_active Ceased
- 2005-04-01 AR ARP050101299A patent/AR049487A1/es not_active Application Discontinuation
- 2005-04-01 UY UY28839A patent/UY28839A1/es unknown
- 2005-04-01 TW TW094110566A patent/TW200539872A/zh unknown
-
2006
- 2006-10-03 IL IL178427A patent/IL178427A0/en unknown
- 2006-10-31 NO NO20064974A patent/NO20064974L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20064974L (no) | 2006-10-31 |
AU2005229459A1 (en) | 2005-10-13 |
BRPI0509515A (pt) | 2007-09-11 |
CA2560417C (en) | 2011-04-19 |
CA2560417A1 (en) | 2005-10-13 |
UY28839A1 (es) | 2005-11-30 |
AU2005229459B2 (en) | 2008-09-25 |
RU2006135482A (ru) | 2008-05-10 |
AU2005229459B9 (en) | 2009-01-22 |
IL178427A0 (en) | 2007-02-11 |
RU2377238C2 (ru) | 2009-12-27 |
JP2007531723A (ja) | 2007-11-08 |
US20070208059A1 (en) | 2007-09-06 |
TW200539872A (en) | 2005-12-16 |
EP1735287A1 (en) | 2006-12-27 |
JP4177435B2 (ja) | 2008-11-05 |
US7799804B2 (en) | 2010-09-21 |
KR20060133084A (ko) | 2006-12-22 |
WO2005095354A1 (en) | 2005-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049487A1 (es) | Compuestos de imidazol sustituidos | |
AR054184A1 (es) | Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas. | |
AR054417A1 (es) | Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas. | |
AR047683A1 (es) | Pirazoles para el tratamiento de obesidad y trastornos psiquiatricos | |
AR042658A1 (es) | Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides | |
HRP20140975T1 (hr) | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze | |
RS50755B (sr) | Supstituisani aril i heteroaril derivati kao modulatori metabolizma i profilakse i lečenje poremećaja proisteklih iz toga | |
RS52061B (en) | PIRAZOLYL-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | |
AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
AR063625A1 (es) | COMPUESTOS HETEROCICLICOS eTILES COMO AGENTES ANTICANCEROSOS | |
UY28374A1 (es) | Agentes terapéuticos | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
AR052330A1 (es) | Derivados de adamantano que comprenden quinoleinas sustituidas | |
AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
EA200702469A1 (ru) | Замещенные производные оксадиазола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
BRPI0608216A2 (pt) | agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo | |
WO2006136837A3 (en) | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | |
AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
JO2741B1 (en) | Spiro-cyclic nitroblast as protease inhibitors | |
CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
BRPI0519292A2 (pt) | compostos orgÂnicos | |
PL1831202T3 (pl) | Pochodne pirolidyniowe jako receptory M3 muskarynowe | |
AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |